您搜索了: trombastenija (马耳他语 - 英语)

noveseven ġie wkoll studjat f’ pazjenti bi trombastenija ta ’ glanzmann li ma setgħux jirċievu platelets.
novoseven has also been studied in patients with glanzmann’ s thrombasthenia who could not receive platelets.

novoseven ġie wkoll studjat f’pazjenti bi trombastenija ta’ glanzmann li ma setgħux jiġu kkurati bil-pjastrini.
novoseven has also been studied in patients with glanzmann’s thrombasthenia who could not be treated with platelets.

fi trombastenija ta’ glanzmann, id-doża hija 90 mikrogramma/kg kull sagħtejn, għal minimu ta’ tliet dożi.
in glanzmann’s thrombasthenia, the dose is 90 micrograms/kg every two hours, for a minimum of three doses.

noveseven jintuża għat- trattament u l- prevenzjoni ta ’ emorraġiji konnessi mal- kirurġija f’ dawn il - gruppi ta ’ pazjenti li jmiss: • pazjenti b’ emofilija konġenita (problema ta ’ emorraġija li tkun teżisti sa mit- twelid) li jkunu żviluppaw jew li jkunu mistennija li jiżviluppaw ‘ inibituri ’ (antibijotiċi) kontra l- fattur vii jew ix; • pazjenti b’ emofilija akkwiżita (marda kkawżata mill- iżvilupp spontanju ta ’ inibituri għall- fattur viii); • pazjenti b’ defiċjenza konġenita tal- fattur vii; • pazjenti bi trombastenija ta ’ glanzmann (tip ta ’ disturb rari ta ’ emorraġija) li ma jkunux jistgħu jiġu trattati bi transfużjoni tal- platelets (komponenti li jgħinu fit- tagħqid tad- demm).
novoseven is used for the treatment and prevention of bleeding connected with surgery in the following groups of patients: • patients with congenital haemophilia (a bleeding disorder present from birth) who have developed or are expected to develop ‘ inhibitors ’ (antibodies) against factor viii or ix; • patients with acquired haemophilia (a disease caused by the spontaneous development of inhibitors to factor viii); • patients with congenital factor vii deficiency; • patients with glanzmann’ s thrombasthenia (a rare bleeding disorder) who cannot be treated with a transfusion of platelets (components that help the blood to clot).